Experimental drug offers hope for cancer patients with depleted immune cells
NCT ID NCT06956547
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This expanded access program provides nogapendekin-alfa inbakicept (NAI) to adults with solid tumors who have low lymphocyte counts caused by prior cancer treatments like chemotherapy, immunotherapy, or radiation. The goal is to reverse and maintain healthy lymphocyte levels. It is for patients who cannot join a clinical trial and will receive NAI injections every 2-3 weeks alongside their standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon - Shiong Institute for Medicine
AVAILABLEEl Segundo, California, 90245, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nogapendekin-alfa inbakicept (NAI)
What this could lead to
If it works, this could help restore immune cell levels in cancer patients whose lymphocyte counts dropped due to chemotherapy, immunotherapy, or radiation.
What could go wrong
This is an expanded access program, not a formal trial, so results are not systematically collected. It is only for patients who cannot join a clinical trial, and benefits are uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.